JAZZ News and Press, Jazz Pharmaceuticals plc From 08/03/22

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.30 beats by $0.11 . Revenue of $932.88M (+24.1% Y/Y) beats by $30.37M . 2022 total revenue guidance affirmed at $3.5B to $3.7B vs. consensus of $3.6B. "We have achieved our net lever...

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of ...

Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More importantly, the firm indicated its upcoming labeling discussion for AXS05 with the ...

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 PR Newswire DUBLIN , July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results...

It's been a sad year for most investors, at least so far. With the S&P 500 in bear market territory (a drop of 20% or more from its most recent highs) and persistent geopolitical and economic problems, it's not clear that the end of these troubles is in sight. But some equities are ...

Cantor Fitgerald raised its price target on commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) by as much as ~36% noting that the company’s management provided a much clearer view on sleep disorder therapy Sunosi at an investor event on Tuesday. In Ma...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666 ) evaluating nabiximols oromucosal spray (JZP378, or Sativex , ex-U.S.) on clinical measures of spasticity in individuals with multiple sclerosis (MS). ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple sclerosis (MS) spasticity. MS is a potentially disabling disease affecting the central nervous syste...

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity PR Newswire Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple s...

Bear markets don't last forever. They also give forward-thinking investors plenty of opportunities to buy great stocks at a discount. We asked three Motley Fool contributors to identify stocks they think could double by 2025. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM...